DTIL
PRECISION BIOSCIENCES INC
NASDAQ · Healthcare · Biotechnology · US
$7.71
+10.66%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.21
From 52W high−16.88%
Volume250218.00
Market cap$215.48M
P/E (TTM)—
P/S (TTM)4.8x
Div yield—
Key dataNov 4, 2026
Open
$7.21
From 52W high
−16.88%
Volume
250218.00
Market cap
$215.48M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
P/E (TTM)
—
RSI (14)
61.5
MomentumView details →
1D Return
+10.66%
YTD Return
+80.22%
SummaryUpdated Sep 1, 2026
Precision BioSciences, Inc. (NASDAQ:DTIL) is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina. The company went public in March 2019 and focuses on developing advanced gene editing therapies to treat genetic disorders and cancer. Precision BioSciences operates at the cutting edge of biotechnology, utilizing proprietary gene editing platforms to create both in vivo therapies that work directly within patients' bodies and ex vivo treatments that modify cells outside the body before reintroduction.
Similar companies
Latest newsMore news →
Precision BioSciences reported financial results for the third quarter ended September 30, 2026, and provided a business update.1d agoPrecision BioSciences announced that it will publish its third-quarter 2026 financial results and provide a business update on November 3, 2026.6d agoPRECISION BIOSCIENCES INC announced that it was selected to deliver a late-breaking oral presentation on PBGENE-HBV at The Liver Meeting 2026.27d ago